Quote:

---

"75% of the patients who exhibited a lower level of circulating cells after leronlimab (86%) or at baseline (14%) exhibited a 3600% increase in 12-month Overall Survival (“OS”) (p = 0.0004), as compared to a 980% increase in OS reported by the Company on August 25, 2021."

---

Overall Survival for the entire cohort of patients was 980%. The subset is patients that had lower initial CTCs or that had lower CTCs after using leronlimab. 75% of the patients from that subset showed a 3600% increase in overall survival. What I'd like to know is what is the percentage of patients in that subset compared to the total number of patients.